Furan-2-yl[4-(2-methyl-4-nitrophenyl)piperazin-1-yl]methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Furan-2-yl[4-(2-methyl-4-nitrophenyl)piperazin-1-yl]methanone
• 英文别名: furan-2-yl-[4-(2-methyl-4-nitrophenyl)piperazin-1-yl]methanone
• 化学式: C16H17N3O4
• 分子量: 315.32
• InChiKey: SVMQYZRDIQLLHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  82.5
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS
  申请人：Schwiebert Erik M.

  公开号：US20140073632A1

  公开（公告）日：2014-03-13

  Novel CFTR corrector compounds that are effective in rescuing halide efflux in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of screening for CFTR corrector compounds are also described herein. The methods of screening include contacting a cell that endogenously expresses a CFTR mutation with the compound to be screened and detecting a rescue of halide efflux from the cell.
• US9221840B2
  申请人：——

  公开号：US9221840B2

  公开（公告）日：2015-12-29
• [EN] TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS<br/>[FR] TRAITEMENT DES TROUBLES LIÉS AU REPLIEMENT DES PROTÉINES AVEC DES CORRECTEURS DE CFTR À PETITE MOLÉCULE
  申请人：DISCOVERYBIOMED INC

  公开号：WO2012158913A2

  公开（公告）日：2012-11-22

  Novel CFTR corrector compounds that are effective in rescuing halide efflux in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The methods include administering a CFTR corrector compound or pharmaceutically acceptable salt or prodrug thereof. Methods of screening for CFTR corrector compounds are also described herein. The methods of screening include contacting a cell that endogenously expresses a CFTR mutation with the compound to be screened and detecting a rescue of halide efflux from the cell.